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ABSTRACT 
Objective: The rationale of the current research work was to formulate and evaluate fast-dissolving tablets of doxazosin mesylate with minimum 
disintegration time and improved dissolution efficiency using solid dispersion method. 
Methods: Solid dispersions of doxazosin mesylate and polyethylene glycol 8000 in different ratios were prepared using the kneading method. The 
prepared solid dispersions were subjected to drug interaction and dissolution studies to select the effective solid dispersion for the formulation of 
fast-dissolving tablets. Fast dissolving tablets containing drug-polyethylene glycol 8000 solid dispersion (1:3) were prepared using various super-
disintegrants such as crospovidone, croscarmellose sodium, mixture and coprocessed crospovidone and croscarmellose sodium in concentration 
range of 2% and 5% by direct compression technique. The prepared formulations (F1–F16) were evaluated for post compression parameters; 
hardness, thickness, friability, wetting time, disintegration time, and in–vitro drug release.  
Results: Drug doxazosin mesylate showed enhanced aqueous solubility of 13.3µg/ml in the presence of polyethylene glycol 8000. Differential 
scanning calorimetery and Fourier transform infrared spectroscopy studies confirmed no interaction between drug and polyethylene glycol 
8000and, drug-polyethylene glycol 8000 solid dispersion showed cumulative drug release of 44.48% in 60 min. Formulated FDT of drug-
polyethylene glycol 8000 solid dispersion, containing coprocessed mixture of crospovidone and croscarmellose sodium (5%) exhibited 
disintegration time of 14.5s with percentage cumulative release of 92.46% in 60 min. 
Conclusion: The work reasonably concludes that for the formulated doxazosin mesylate-fast dissolving tablets, disintegration time was effectively 
reduced by the presence of coprocessed mixture of crospovidone and croscarmellose sodium and dissolution efficiency was improved by 
preparation of solid dispersion with polyethylene glycol 8000. 
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To overcome constraints of oral route for geriatric, pediatric, and 
travelling patients, modern advances in the pharmaceutical 
technology have prompted scientists to develop fast dissolving 
tablets (FDT) with improved patient compliance and convenience. 
FDT are the most extensively employed commercial product and 
also become a promptly growing field in the pharmaceutical 
industry. They are the oral solid dosage form, which dissipate 
instantaneously in the oral cavity when placed upon the tongue and 
also swallowed without the aid of water. FDTs are also called as 
rapid melts, melt-in-mouth tablets, porous tablets, or quick-
dissolving tablets. The drugs dissolve in the saliva and absorbs 
gradually when passes from the mouth, pharynx, esophagus and into 
the stomach thereby improving the bioavailability, which is 
significantly greater than the conventional oral dosage forms [1-8].  
Solid dispersion is one of the accepted approaches for dissolution 
enhancement. They are molecular mixtures of poor water soluble 
drugs with hydrophilic carriers prepared by solvent evaporation 
and melting method. They provide better wettability and 
dispersibility as the drug is in its supersaturated state due to forced 
solubilisation in the hydrophilic carriers. Literature supports many 
successful commercial products based on solid dispersion 
techniques. [9, 10] 
Doxazosin mesylate (DM), a quinazoline derivative, could be used in 
the treatment of mild to moderate hypertension and also in the 
management of symptomatic benign prostatic hyperplasia (BPH). In 
hypertensive patients, DM reduces the blood pressure by selectively 
antagonizing the postsynaptic α1-adrenergic receptors. DM is a BCS 
class II drug with poor aqueous solubility and high permeability and 
undergo hepatic first pass metabolism resulting in reduced 
bioavailability. [11-15]. Though literature supports studies on DM 
with respect to taste making oral disintegrating tablet, [16] 
Sustained release [17] and controlled release dosage system [11] 
and not much work has been reported with respect to solubility 
enhancement for management of hypertension in emergency 
situation. Hence in the present study an attempt was made to increase 
the solubility of DM by preparation of its solid dispersion and 
formulated into FDTs using various superdisintegrants with the 
objective of reducing first pass effect by enhancing solubility, 
minimizing disintegration time, with improved drug dissolution rate. 
MATERIALS AND METHODS 
The active pharmaceutical ingredient DM was procured from 
Yerrow Pharmaceuticals Pvt. Ltd., Maharashtra. CRP was procured 
from International specialty product, Hongkong Ltd, CCS and 
microcrystalline cellulose (MCC) was procured from The Anglo 
French Drug Co. Limited, Bengaluru. The other excipients 
polyethylene glycol (PEG), sucrose, lactose, magnesium stearate, 
talc, methanol were procured from SD fine fhemicals limited, 
Mumbai. All chemicals used in the project were analytical grade. 
Phase solubility studies 
Solubility studies were performed according to method described by 
Higuchi and Connors [18-19] using different polymers like PVP K30, 
PEG 4000, PEG 8000 and urea. An excess amount of drug was taken 
into a screw-capped glass vial to which 20 ml of aqueous solution 
containing various concentrations (2-10%) of polymer was added. 
The solvent was equilibrated by shaking for 72 h in a rotary shaker. 
After attainment of equilibrium, the content of each flask was 
filtered. The filtrate was diluted suitably and assayed 
spectrophotometrically at the wavelength of 246 nm using UV-
spectrophotometer (Shimadzu UV-1700 PC, Japan). The solubility of 
drug in different polymers was determined using standard graph. 
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Preparation of solid dispersion of DM using polyethylene glycol 
8000 
Solid dispersions were prepared using the kneading method. In this 
process, mixture of DM and PEG 8000 in different ratios (1:1, 1:2, 
and 1:3) were weighed accurately and wetted with methanol and 
kneaded for 30 min in a mortar and pestle. The obtained paste was 
dried under vacuum for approximately 24 h. Dried powder attained 
was scrapped, pulverized, and passed through a sieve number 60 
and further used in the formulation of FDTs [20, 21].  
Evaluation of solid dispersion  
Fourier transform infrared spectroscopy (FTIR) analysis 
Infrared spectroscopy is a useful analytical technique utilized to 
check the chemical interaction between the drug and other 
excipients used in the formulation. Small quantity of the sample was 
powdered and intimately mixed with 10 mg of dry powdered 
potassium bromide. The powdered mixture was taken in a diffuse 
reflectance sampler and the spectrum was recorded by scanning in 
the wave number region of 4000-400 cm-1 in an FTIR 
spectrophotometer (Jasco 460 plus, Japan). The IR spectrum of the 
drug was compared with that of the physical mixture to check for 
any possible drug-excipients interaction [22, 23]. 
Differential scanning calorimetry (DSC) 
DSC was carried out on Mettler Toledo DSC-1. DSC examination was 
conducted for pure drug, polymer and solid dispersion of drug. 
Samples of 2-10 mg were placed in aluminium pans and sealed. The 
probes were heated from 40-300 °C at a rate of 10 °C/min under 
nitrogen atmosphere. Melting points and phase transitions were 
measured at peak minimum of each DSC thermograph. The DSC was 
calibrated with an indium standard. The DSC was used to determine 
the melting point and purity of DM [22-24].  
Dissolution studies of solid dispersion  
In vitro dissolution study of dispersion was performed using USP 
(type II) apparatus at a speed of 50rpm. Dissolution study was 
carried out using 900 ml of phosphate buffer of 6.8 pH and the 
dissolution medium was maintained at a temperature of 37 °C±0.5 
°C. At appropriate intervals, 1 ml of solution was taken and filtered. 
The dissolution medium was then replaced with 1 ml of 6.8 pH 
buffer to maintain sink conditions. The samples were analyzed at 
246 nm by UV/visible spectrophotometer using 6.8 pH buffers as 
blank. The pH was selected based on the literature review on FDT. 
Since it is fast dissolving tablet it is exposed at first to saliva pH, 
which ranges from 6.2-7.2 and average pH is nearly 6.8. The mean of 
three determinations was used to calculate the drug release from 
each formulation [23-25]. 
Formulation of FDT containing DM-PEG 8000 solid dispersion  
The physical mixture of CRP and CCS in the ratio of 1:1 was prepared 
by physically mixing both for 15 min and co-processed mixture 
mixture was prepared by solvent evaporation method. The drug DM, 
PEG 8000 solid dispersion (1:3), sucrose, MCC (microcrystalline 
cellulose), lactose, and talc were weighed accurately and mixed 
separately with CRP, CCS, physical mixture and co-processed 
mixture for 15 min to obtain a uniform blend. The resulted blend 
was further lubricated with magnesium stearate for 5 min and 
compressed into tablet with an average weight of 100 mg using a 6.7 
mm round flat punch in a rotary tablet press (Rimek RSB-4 
Minipress, Ahmedabad). [26,27] The corresponding composition of 
each formulation is mentioned in the tables 1. 
 
Table 1: Composition of doxazosin mesylate FDT’s 
Ingredients in mg F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 
DM-PEG 8000 solid dispersion 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32 
MCC 45 45 30 30 45 45 30 30 45 45 30 30 45 45 30 30 
Sucrose 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
CRP 2 5 2 5 - - - - - - - - - - - - 
CCS - - - - 2 5 2 5 - - - - - - - - 
PM CRP+CCS - - - - - - - - 2 5 2 5 - - - - 
CP CRP+CCS - - - - - - - - - - - - 2 5 2 5 
Talc 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 2 
Lactose 14 12 29 27 14 12 29 27 14 12 29 27 14 12 29 27 
Magnesium stearate 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Total weight of the tablet 100 mg each tablet  
PM: Physical mixture of CRP and CCS CP: Co-processed mixture of CRP and CCS 
 
Tablet evaluation parameters  
Hardness 
Hardness test was done to determine the resistance of tablets while 
shipping, storage, handling, and transportation. A total of 10 tablets 
were selected arbitrarily and measured by using a Monsanto 
hardness tester (Campbell Electronics, Mumbai). The tablet was 
kept in tester and force was applied until the tablet gets fractured. 
The data obtained were expressed in kg/cm2. 
Friability 
Variability of the tablets was estimated by friabilator (Electrolab EF-
2, India), expressed in percentage. A total of 10 tablets chosen 
arbitrarily were weighed and taken into the apparatus and operated 
for 4 min at 25 rpm. After a specific period, the tablets were 
reweighed. The friability was then determined by the below formula 
Friability =  
Initial weight − Final weight 
Initial weight
 X 100 
Weight variation 
A total of 20 tablets from each batch were selected and weighed 
individually. The average weight was then determined and compared 
with individual weight to know any deviation from average weight. 
According to USP the batch passes the test if not more than two tablets 
deviated outside the specified percentage limit (±7.5%).  
Drug content 
A total of 10 tablets were selected arbitrarily and crushed into a fine 
powder. The powder, that is equivalent to 10 mg of standard drug was 
dissolved in 10 ml of methanol and diluted to 100 ml with 6.8 pH 
phosphate buffer. The absorbance of the resultant solution was 
measured by an ultraviolet (UV) spectrophotometer at 246 nm, 
against the same buffer as the reference solution. Based on the 
readings obtained, the amount of drug in each tablet was determined.  
Wetting time 
The each formulated tablet was retained carefully on a tissue paper and 
placed in a petri dish having 6 ml of water. The time taken to complete 
wetting of the tablet was taken as wetting time. For each batch three 
trials were conducted and standard deviation was determined. 
Disintegration test 
The disintegration time of FDTs was accomplished using USP 
disintegration test apparatus II (Electrolab ED-2, India). Formulated 
tablets were kept in six disintegration tubes and secured with discs 
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placed in each tube to prevent floating of tablets. Distilled water, 
used as a disintegration medium, was kept at 37 °C±0.5 °C. The time 
consumed by each FDT to disintegrate completely without any 
residue remaining was recorded [28-32].  
In vitro dissolution studies 
Dissolution studies of FDTs of each batch were accomplished by 
using USP paddle type II dissolution apparatus (TDT-08L, Electrolab, 
India) at 50 rpm. Also, 900 ml of 6.8 pH phosphate buffer as 
dissolution medium was maintained at 37±0.5 °C. Test sample (1 ml) 
was withdrawn at predetermined intervals and replaced with the 
same volume of fresh and pre warmed 6.8 pH buffer to preserve the 
sink conditions. The drawn samples were diluted with 6.8 pH buffer 
in a 10 ml volumetric flask and analyzed at 246 nm in a UV 
spectrophotometer against 6.8 pH buffer as the reference solution. 
The percentage cumulative drug release was calculated [33, 34]. 
RESULTS AND DISCUSSION 
Phase solubility study 
In this study, an attempt has been made to increase the solubility of 
DM in the preparation of solid dispersion and formulate FDTs of DM 
using various techniques. Initially phase solubility studies were 
carried out in aqueous 6.8 Phosphate buffer at 37 °C. It was 
observed that the solubility of DM increased linearly along with the 
concentrations of carriers (AL-type diagrams) fig. 1. This indicates 
that drug and carrier forms 1:1 complexes. [35] Carrier PEG 8000 
showed maximum solubility of 14 μg/ml with R2 value of 0.989 and 
hence selected for DM solid dispersions. 
 
 
Fig. 1: Phase solubility study of drug DM with carriers in aqueous 6.8 phosphate buffer (n=3) 
 
Preparation and evaluation of solid dispersion 
FTIR 
In order to check possible drug-excipients interaction, the infra-red 
spectra of DM, PEG-8000 and solid dispersion of DM-PEG-8000 were 
recorded using FTIR spectrophotometer.  
Distinct peak in the region 2982-2862 cm-1 for C-H aliphatic, 1350-
1000 cm-1 for C-N amine and 3500-3100 cm-1 secondary amine, 
3450-3300 cm-1 for N-H group, 3200-3000 cm-1 for = C-H group and 
1900-1600 cm-1 for C=O group was identical to that off which 
confirm the compatibility of the drug and carrier. The spectra are 




Fig. 2: FTIR spectra of drug DM, carrier PEG 8000 and solid dispersion of DM with PEG 8000 
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DSC study was carried out to find out the possible interaction 
between drug DM and polymer PEG-8000. Pure DM powder 
showed endothermic peak at 276.35 °C with enthalpy of fusion 
(ΔH) 89.61 J/g and PEG at 63.51 °C corresponding to its melting 
point. The DSC analysis of solid dispersion reveled negligible 
change in melting point of DM and PEG-8000 in the drug 
polymer complex (DM-PEG-8000 solid dispersion). The retention 
of this characteristic endothermic peak of drug (fig. 3) thus 




Fig. 3: DSC of DM, carrier PEG 8000 and solid dispersion of DM with PEG 8000 
 
In vitro dissolution of solid dispersion  
The solid dispersion prepared was subjected to in vitro dissolution 
studies using USP type II dissolution apparatus. The release data 
obtained through dissolution studies is shown in fig. 4. The release 
profile obtained demonstrated that as the ratio of carrier increased 
the percentage release also increased. It was noticed that at the end 
of 60 min, solid dispersion of PEG 8000 (1:3) exhibited the highest 
cumulative release of 44.48 %. The enhanced dissolution of the drug 
in the presence of PEG may be due to the increased wetabillity of the 
drug by the formation of a film of polyethylene glycol around the 
drug substance particles, which modifies the hydrophobicity of the 
surfaces. [36, 37] Hence the solid dispersion of DM: PEG 8000 (1:3) 
was chosen for the formulation of FDTs. 
 
 
Fig. 4: In vitro dissolution profile of pure drug DM and its solid dispersion with PEG 8000 (n=3) 
Preethi et al. 
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Evaluation of FDT tablets 
Drug DM is a BCS class II drug and best suitable for FDT Based on 
the literature survey, CCS and CRP were employed as the super 
disintegrants for the current investigation [38-40]. The selected 
solid dispersion was blended with CCS, CRP and other excipients 
mentioned in the table 1 and total of 16 formulations were subjected 
to post compression parameters.  
Post compression studies were conducted for the formulations 
(F1–F16) to determine the physical characteristics. Tablet 
thickness was found to range from 2.25 to 2.32 mm. Tablets of all 
the batches were found to exhibit sufficient hardness, ranging 
from 2.3 to 3 kg/cm2. Wetting time of the tablets was found to be 
in the range of 16.2–37.5 s. Friability values range from 0.26 % to 
0.54 % which was found to be within limits. Drug content of all the 
formulations was found to range from 67.31 to 76.59 mg of DM, 
which was within acceptable limits. All the formulations passed 
the weight variation test as percent weight variation was within 
the pharmacopoeial limits of 10.0 % (table 2). Disintegration time 
of these formulations (F1–F16) was found to be in the range of 
14.5–34 s. Increase in the concentration of CRP (2 % and 5 %) was 
found to be beneficial in reducing the disintegration time. Similar 
results were attained with CCS (2 % and 5 %). The decrease in 
disintegration time may be attributed to greater porosity and 
strong swelling at higher concentration of disintigrants. [39] 
However, addition of physical mixture and co-processed mixture 
of CRP and CCS reduces the disintegration time to a greater extent. 
Tablets prepared using a physical mixture of CCS and CRP sodium 
showed a disintegration time in range of 24.5–34 s, which was 
comparatively less than that obtained with CCS and CRP sodium 
used individually. This may be due to the synergetic effect of the 
co-processed mixture compared to simple physical mixture. [40, 
41] In comparison with physical mixture used, the least 
disintegration time of 14.5 s was obtained with F16 formulation 
containing 5 % co-processed mixture of CCS and CRP. The 
corresponding results obtained are depicted in tables 2. 
 
Table 2: Post-compression evaluation of FDT’s 
Test  Thickness* (mm) Hardness* (kg/cm2) Friability (%) % Drug content Weight variation WT* (sec) DT*(s) 
F1 2.26±0.20 2.8±0.06 0.34±0.52 72.47 98±0.25 35.5±0.048 31.0±0.05 
F2 2.8±0.12 2.9±0.25 0.32±0.24 73.12 99±0.38 33±0.455 32.5±0.24 
F3 2.27±0.56 2.5±0.09 0.41±0.96 75.21 106±0.64 28.4±0.472 26.5±0.61 
F4 2.28±0.02 2.4±0.27 0.44±0.34 75.81 99±0.09 37.5±0.870 29.0±0.29 
F5 2.3±0.39 2.9±0.62 0.31±0.08 70.26 95±0.78 32.8±1.032 24.5±0.07 
F6 2.32±0.41 2.8±0.34 0.42±0.67 72.71 96±0.36 35.9±1.462 34.0±0.18 
F7 2.29±0.09 2.6±0.05 0.32±0.49 71.22 103±0.54 30.4±0.582 27.5±0.91 
F8 2.28±0.26 2.5±0.42 0.53±0.61 73.47 94±0.28 27.3±1.628 30.0±0.52 
F9 2.25±0.54 2.9±0.81 0.31±0.30 67.31 99±0.05 25.1±0.897 27.0±0.46 
F10 2.3±0.31 3.0±0.26 0.54±0.49 69.92 94±0.57 25.8±1.048 21.5±0.08 
F11 2.29±0.30 2.4±0.37 0.52±0.12 72.51 105±0.62 22±0.001 25.5±0.62 
F12 2.25±0.73 2.6±0.94 0.30±0.29 73.03 97±0.84 21.3±1.414 21.0±0.74 
F13 2.6±0.54 2.9±0.28 0.42±0.47 73.65 98±0.64 22.3±0.279 19.5±0.69 
F14 2.28±0.04 3.0±0.07 0.39±0.38 71.03 96±0.35 17.9±0.023 17.0±0.38 
F15 2.28±0.12 2.3±0.59 0.29±0.08 68.48 102±0.72 17.5±0.376 16.5±0.16 
F16 2.3±0.42 2.6±0.62 0.26±0.51 76.59 110±0.08 16.2±0.250 14.5±0.24 
WT: Wetting time, DT: Disintegration Time *Average of three readings±SD 
 
Formulation F16 having MCC (30 %) and co-processed mixture of 
CRP and CCS (5 %) released maximum medicament, which was 
found to be 92.46±0.19 % in 60 min (fig. 5). The rapid drug 
dissolution may be due to the presence of super disintegrants, which 
swells due to the rapid uptake of water from medium resulting in 
breakdown of tablet into smaller particles with increased surface 
area and hence increased release of the drug into the dissolution 
medium. Formulations F13, F14, and F15 showed the release of 
83.85±0.12 %, 85.58±0.26 %, 89.1±0.26 % in 60 min, respectively. 
These results clearly indicated that FDTs of DM-PEG 8000 solid 
dispersion can be prepared by direct compression method by 
incorporation of co-processed mixture of CCS and CRP. 
 
 
Fig. 5: In vitro dissolution of formulated FDTs (F1-F16) (n=3) 
Preethi et al. 




In the current investigation it was demonstrated that the solid 
dispersion of DM prepared using PEG-8000 improved the dissolution 
properties of poorly water soluble drug DM and could be included in 
formulation of FDT. Among various super-disintegrants used in FDT, 
co-processed mixture of CRP and CCS 5% played an important role in 
decreasing disintegration time and enhanced the drug release. Further 
investigations are required to understand the feasibility of formulated 
FDT of DM for the management of hypertension.  
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